SLC5A2 and chronic kidney disease: The glucose-lowering effects of SGLT2 inhibitors are achieved via glucosuria, and are comparatively modest, reducing HbA1c by 0.5-0.7% in patients with normal kidney function, and lesser effects are seen in patients with CKD stage 3 or 42,44.